CB Therapeutics Is Breaking New Ground in Bioinformatics, Gene Design, Protein Engineering and Process Engineering
CB Therapeutics Is Breaking New Ground in Bioinformatics, Gene Design, Protein Engineering and Process Engineering
Advancing Bioinformatics
Structural and bioinformatics programs that we developed in-house allow for novel enzyme design and a rapidly growing IP portfolio platform. Our innovative proprietary automated transcriptome assembly in the cloud requires marginal human input and is scalable to assemble any number of transcriptomes. We are making new discoveries from multiple plant species on a weekly basis.
Advancing Biosyn Gene Design
We are utilizing cutting edge gene design techniques for more robust enzyme expression in proprietary strains of yeast. Our novel and proprietary enzyme engineering platform has rapidly pushed ever higher titers and the development of improved platforms and processes, presently scaled up to hundreds of liters in-house.
Advancing Process Engineering
Our advanced Bioinformatics platform allows us to conduct complex structural analyses that lead to higher yields with greater efficiency and consistency. Several additional patents are in development that show additional yield improvements and better extraction techniques for multiple yeast derived high value products. Our quick process development for production, and additional third-party resource support, prevents fermentation bottlenecking. We have achieved the significant acceleration of continuous extraction, enzyme prediction, and discovery while increasing production throughput.
Advancing Protein Engineering
Our protein engineering for many of our products begins with multiple functional enzymes rather than just a single one. These functional enzymes and how they come together to enhance product titers are unique to our science. Our bioinformatics and protein engineering platforms have optimized these enzymes to hyper-function in our proprietary yeast strains.
